STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study
Status:
Unknown status
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the activity of fixed doses of cisplatin and
etoposide with toxicity adjusted dosing of the same drugs in the first-line treatment of
small cell lung cancer.